Table I.
Bleo group | Bleo + non-CM group | Bleo + AMTC-CM group | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 9 | Day 14 | Day 9 | Day 14 | Day 9 | Day 14 | ||||||||||
M | IQR | M | IQR | P | M | IQR | M | IQR | P | M | IQR | M | IQR | P | |
Fibrosis distribution | 1.5 | 1.0 | 3.0 | 1.8 | < 0.05 | 1.0 | 0.5 | 2.5 | 2.0 | < 0.01 | 1.0 | 0.3 | 1.0 | 0.9 | NS |
Fibroblast proliferation | 0.7 | 0.4 | 1.6 | 1.0 | < 0.01 | 0.2 | 0.3 | 1.5 | 1.2 | < 0.01 | 0.7 | 0.5 | 0.8 | 0.4 | NS |
Collagen deposition | 1.2 | 0.3 | 2.0 | 1.2 | < 0.05 | 1.0 | 0.8 | 2.2 | 1.0 | < 0.01 | 1.0 | 0.5 | 1.4 | 0.5 | NS |
Alveolar obliteration | 2.7 | 0.8 | 3.2 | 0.5 | NS | 2.3 | 0.8 | 3.1 | 1.2 | < 0.05 | 2.5 | 1.2 | 2.3 | 0.8 | NS |
Fibrosis progression was observed in the control groups (Bleo and Bleo + non-CM) from days 9 to 14, but was absent in the AMTC-CM treated group.
Median (M) with IQR of scores obtained from animals of the same group at each time-point. The statistical differences between time-points of each group are reported as P-values, which were calculated as described in the Methods. NS, not significant.